Get the Stockscreener App
2.77
4.81%
-0.14
After Hours:
2.83
0.06
+2.17%
Savara Inc stock is traded at $2.77, with a volume of 1.60M.
It is down -4.81% in the last 24 hours and up +11.24% over the past month.
See More
Previous Close:
$2.91
Open:
$2.81
24h Volume:
1.60M
Relative Volume:
1.63
Market Cap:
$485.68M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-8.3939
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
-2.12%
1M Performance:
+11.24%
6M Performance:
-34.67%
1Y Performance:
-44.38%
1-Day Range:
$2.68
$2.88
1-Week Range:
$2.61
$2.94
52-Week Range:
$2.31
$5.34
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.77 | 485.68M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - MarketScreener
SAVARA Earnings Preview: Recent $SVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Savara Inc ends sales agreement with Evercore - Investing.com
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval - Investing.com
Swiss National Bank Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
What is HC Wainwright’s Estimate for Savara Q1 Earnings? - Defense World
HC Wainwright Reaffirms Buy Rating for Savara (NASDAQ:SVRA) - Defense World
Savara enters loan and security agreement with Hercules Capital - MSN
Savara stock holds Buy rating, $6 target from H.C. Wainwright By Investing.com - Investing.com Australia
Savara stock holds Buy rating, $6 target from H.C. Wainwright - Investing.com India
Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc. (SVRA) reports earnings - Quartz
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Joplin Globe
JMP maintains $9 target on Savara stock, sees FDA nod By Investing.com - Investing.com South Africa
JMP maintains $9 target on Savara stock, sees FDA nod - Investing.com India
Savara secures $200M loan to support respiratory drug launch By Investing.com - Investing.com South Africa
Savara secures $200M loan to support respiratory drug launch - Investing.com
Savara Gets Up to $200 Million Loan From Hercules Capital - Marketscreener.com
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Bluefield Daily Telegraph
Major Financial Boost: Savara Lands $200M Debt Deal as FDA Decision Approaches - Stock Titan
Savara submits FDA application for aPAP therapy MOLBREEVI - Investing.com
Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Marketscreener.com
Breakthrough: First Treatment for Rare Lung Disease aPAP Heads to FDA Review - Stock Titan
Bank of New York Mellon Corp Purchases 17,870 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ: SVRA) Stock: Investors Need To Know This - Stocks Register
Victory Capital Management Inc. Reduces Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Savara Inc (NASDAQ:SVRA) Receives $8.83 Consensus Price Target from Analysts - Defense World
Savara Inc. to Present at Leerink Global Healthcare Conference - MSN
Breakthrough Phase 3 Results: New Treatment Reduces Lung Procedures in Rare Disease Patients - StockTitan
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Oppenheimer & Co. Inc. Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Rhumbline Advisers Purchases 9,041 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ: SVRA): An Enticing Stock To Watch - Stocks Register
Savara, Inc. to Host Earnings Call - ACCESS Newswire
Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell -March 06, 2025 at 08:55 am EST - Marketscreener.com
Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
Game-Changing Finger-Prick Test Could Transform Rare Lung Disease DiagnosisWhat Makes It Special? - StockTitan
Savara Announces Participation in the Leerink Global Healthcare Conference - Joplin Globe
Rare Disease Biotech Savara Sets Key Investor Presentation at Leerink Conference - Stock Titan
Savara (SVRA) Expected to Announce Earnings on Thursday - Defense World
Savara Insiders Lose Out As Stock Sinks To US$2.56 - Simply Wall St
SVRA stock touches 52-week low at $2.58 amid market challenges - Investing.com Australia
SVRA stock touches 52-week low at $2.58 amid market challenges By Investing.com - Investing.com South Africa
Analysts Set Savara Inc (NASDAQ:SVRA) Price Target at $9.86 - Defense World
Savara Inc. Awards Stock Options and RSUs to New Employees - MSN
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):